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meaningful. This equated to the change found following six-
months of treatment.
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OBJECTIVES: Monetary cost, positive values truncated at zero,
violates normality assumption when used as the dependent 
variable in ordinary least squares (OLS) regressions. Log trans-
formation of cost removes the skewness, but the resulting coef-
ﬁcients are not directly interpretable as raw dollars. Simply
taking exponent of ﬁtted regression coefﬁcients causes retrans-
formation bias. Duan’s nonparametric smearing estimator
factors into the mean of the anti-log of the residuals, thus 
correcting retransformation bias. The goal of this analysis is to
apply Duan’s smearing technique to retransform logged costs to
evaluate the incremental cost of ChHD using claims data from
an HMO. METHODS: A 13-item self-assessment questionnaire
identifying ChHD and its severity was developed, validated, and
mailed to 1,380 randomly selected members of a Massachusetts
HMO. Average monthly costs for questionnaire respondents
were calculated by the sum of approved and co-payment
amounts from claims ﬁled between April 1, 2001–December 31,
2003 divided by months of observation. OLS regression of log-
arithm of cost was used, with covariates consisting of a ChHD
dummy, and demographic and co-morbid factors. Using Duan’s
estimator, average monthly incremental cost of ChHD was cal-
culated by multiplying percentage cost increase for ChHD from
the OLS regression by predicted average monthly cost for Non-
ChHD patients (which is the average cost after removing the
effect of the ChHD dummy). RESULTS: 140 of 507 question-
naire respondents were identiﬁed as ChHD. Univariate compar-
ison showed no statistical difference in monthly cost between the
ChHD and Non-ChHD groups (Non-ChHD, $326.98 ± $29.52,
ChHD $270.87 ± $23.59, p = 0.1383). A skewness and kurto-
sis test rejected normality. However, multivariate analysis
showed that ChHD patients had a statistically signiﬁcant
monthly cost increase of 25.2%( ±2.5%) compared to Non-
ChHD (p < 0.001), amounting to an average monthly incre-
mental cost of ChHD of $70.69 (±$7.00) per patient.
CONCLUSIONS: Duan’s smearing estimator may be valid for
inferring incremental cost in OLS regression models of logarithm
of cost.
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OBJECTIVES: Atopic dermatitis (AD) is a common childhood
chronic skin condition. Despite high disease prevalence, up to
20% in some populations, little information is available regard-
ing the burden of disease to children and parent/caregivers. 
An objective of this study was to assess the impact of AD on
parents’/caregivers’ quality-of-life. METHODS: In total, 414 AD
patients, between 2–12 years old were identiﬁed through a ret-
rospective review of outpatient billing records from January,
2001 to December, 2004 from two large physician practices and
were contacted to enroll in the study. Data collected included
patient demographics, comorbidities, treatments, and health 
care resource use. Parents also completed the Parent’s Index of
Quality of Life-Atopic Dermatitis (PIQoL-AD), a 28-item, vali-
dated questionnaire evaluating parents’ needs-based quality-of-
life. Total PIQoL-AD scores can range from zero to 28, with a
higher score indicating greater impaired quality-of-life. One-way
analysis of variance was used to determine statistical signiﬁcance.
RESULTS: Mean patient age was 6.7 (SD ± 3.3) years and 55%
of patients were males. Mean duration and treatment of illness
were 3.0 ± 2.2 years and 20.7 ± 21.4 months, respectively.
Parents’ assessment of disease severity indicated that 82% of
patients had mild AD and 13% of patients had moderate AD.
Patients reporting at least one ﬂare experienced 2.8 ± 2.3 ﬂares
per month; mean duration of ﬂares was 5.2 ± 7.0 days. Disease
ﬂares negatively impacted parents’ quality-of-life. PIQoL-AD
scores worsened among those parents whose child had disease
ﬂares. Mean PIQoL-AD scores were statistically signiﬁcantly
higher (5.9 ± 5.4 vs. 3.0 ± 3.6, p < 0.0001) for those parents
whose child had disease ﬂares compared to those who did 
not have disease ﬂares. CONCLUSIONS: Study ﬁndings will
improve our understanding of the impact of AD on children and
their parents/caregivers and may enhance treatment effects, 
clinical outcomes, and patient and parent/caregiver education.
Further investigation is needed to understand the impact of
atopic dermatitis on parents’ quality-of-life.
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OBJECTIVES: The prevalence of chronic hand dermatitis
(ChHD) and its impact on patient-reported outcomes, including
quality of life (QoL), work and activity impairment, were eval-
uated in a managed care organization (MCO). To date, few
studies have investigated ChHD using a general population-
based approach. METHODS: A validated cross-sectional
patient-reported survey was mailed to 1380 members of a Mass-
achusetts MCO. The survey consisted of: a 13-item clinical ques-
tionnaire identifying ChHD based on signs and symptoms of
dermatitis related to hands, treatment response, and diagnoses
of exclusion; the Skindex-29, a 29-question dermatology-speciﬁc
QoL instrument; and the Work Productivity and Activity Impair-
ment (WPAI) instrument validated for ChHD. Those receiving
the survey were randomly sampled from the general MCO pop-
ulation and a subset population with ≥ two medical claims with
a dermatitis or eczema diagnosis (ICD-9 692 or 691.8). ChHD
patients were compared to patients with other skin conditions
and to Non-ChHD patients to assess their relative QoL and
WPAI measures, respectively. RESULTS: Based on the survey
respondents (36.7% response rate), the prevalence of ChHD 
was 17.5% in the MCO general population, a rate much higher
than previously found (2–12%). QoL and WPAI measures for
the ChHD patients were signiﬁcantly worse than those for their
comparison groups (Skindex score: ChHD = 30.33 ± 17.51,
Other Skin Conditions = 20.05 ± 16.68; Work Impairment:
ChHD = 29.33%, Non-ChHD = 6.85%; Activity Impairment:
ChHD = 33.78%, Non-ChHD = 17.32%; all p < 0.0001).
333Abstracts
CONCLUSIONS: Given that ChHD affects almost one in ﬁve
MCO members, its negative impact on members’ QoL, work and
activity impairment measures is signiﬁcant and should be con-
sidered by MCOs and employers.
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OBJECTIVE: Psoriasis is a common disease with profound
impact on many facets of life; there is physical impairment as
well as reductions in quality of life deﬁned by psychological,
social, sexual and ﬁnancial parameters. Work productivity,
another important component of patients’ overall well-being, has
also been reported to be impacted by psoriasis. The objective of
this study was to determine whether there exists a relationship
between clinical severity of psoriasis and work productivity.
METHODS: To quantify the impact of psoriasis on work pro-
ductivity, 90 patients were surveyed in a clinic setting. Three
severity groups were created based on Psoriasis Area and Sever-
ity Index (PASI) scores: mild <10, moderate = 10–20, and severe
>20. Work impairment was measured using the Work Produc-
tivity Assessment Index (WPAI); physical and mental health 
statuses were assessed using the SF-8; Anxiety/Depression was
assessed using the HADS; other health and employment infor-
mation were also collected. RESULTS: One-third of all subjects
were unemployed at the time of the study with 16.7% of these
subjects (5.5% of all 90 subjects) reporting that they were unem-
ployed because of their psoriasis. A greater percentage of patients
in the moderate and severe groups attributed their unemploy-
ment to psoriasis (33% for each), compared with the mild group
(9.5%). There was a trend toward increasing impairment while
at work with increasing psoriasis severity (severe 24.4%, mod-
erate 17.7% and mild 13.5%). With respect to the percent with
activity impairment, there was a statistically signiﬁcant differ-
ence between the severe group (42%) and the mild group
(20.2%)[all p < 0.05]. CONCLUSIONS: Psoriasis is associated
with work productivity impairment, and the degree of work
impact, missed work, physical and mental health condition and
anxiety/depression status tends to be greater in patients with
more severe skin involvement. These ﬁndings support the need
for aggressive but appropriate treatment of moderate-to-severe
psoriasis.
SMOKING
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Up to now, there are few economic analyses which construct
models taking account of tobacco-associated diseases in Japan.
OBJECTIVES: To develop Markov-model, including various
tobacco-associated diseases to evaluate effects of nicotine-
replacement therapy (NRT) and smoking cessation guidance
therapy. METHODS: To identify various tobacco-associated 
diseases and markov transition probabilities, we organized a
committee including expert physicians. With expert interview,
we developed a Markov-model. RESULTS: We identiﬁed 19
tobacco-associated diseases as major results of smoking, accord-
ing to “Health Risk Appraisal”. The 19 diseases are as follows;
10 cancers—oropharyngeal cancer, esophageal cancer, gastric
cancer, hepatic cancer, rectal cancer, pancreatic cancer, lung
cancer, cervical cancer, renal cancer and bladder cancer; 
4 cardiovascular diseases—hypertensive heart disease, ischemic
heart disease, aneurysm and apoplexy; and 5 other diseases—
pneumonia, chronic bronchitis, asthma, gastric ulcer and cir-
rhosis. Tobacco is thought to increase incidence rate of those 19
diseases. We constructed four node Markov model, “Success (of
smoking cessation)” “Failure” “Death” and “Sick”. “Sick” node
consists of 19 diseases. We also considered a combination of
major diseases. In order to avoid many branches, we settled the
transition probabilities of diseases as a cumulative function of
incidence of each disease. The main assumptions are as follows;
1) Only one disease occurs during each cycle; 2) The risk of each
disease increases as cumulative tobacco consumption increases;
and 3) Smoking affects the incidence rate of the 19 diseases but
does not affect mortality rate from those diseases. One cycle 
in Markov chain is set to 5 year. For future cost-effectiveness
analysis of smoking cessation therapy, we set cost as well as 
transition probability on each branch. CONCLUSIONS: We
developed Markov-model, including various tobacco-associated
disease. In the future, we will take cost-effectiveness analysis to
evaluate smoking cessation therapy using this model.
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OBJECTIVES: The “Smoking Effects Inventory” (SEI) assesses
the degree to which subjects experience both desirable and aver-
sive effects from smoking. To date, no formal psychometric
analyses of the SEI have been published. We therefore tested the
validity and reliability of the pre-speciﬁed grouping of items on
the SEI. METHODS: Data came from three Phase II clinical
trials (n = 626, n = 627, n = 312) of varenicline, developed for
smoking cessation, using an adapted version of the SEI with 12
items (one item on enjoying smoking was added). Each item was
scored on a seven-point scale (one = “Not at all” to seven =
“Extremely”) in response to the experience of the reinforcing
effects of smoking. The pre-speciﬁed domains and single-item
scales were Satisfaction (satisfaction, good taste, enjoying
smoking); Psychological Reward (calming, feeling awake, reduc-
ing irritability, helping concentration, reducing hunger); Aversion
(dizziness, nausea); Enjoyment of Respiratory Tract Sensations;
and Craving Reduction. Conﬁrmatory factor analyses and inter-
nal consistency reliability analyses (Cronbach’s alpha) on multi-
item domains were performed at baseline in each of the three
trials. RESULTS: The postulated multidimensional framework of
the SEI was supported by conﬁrmatory factor analysis in each of
the three studies. Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) in the three trials exceeded 0.90 (CF = 0.94,
0.95, 0.94; NNFI = 0.92, 0.93, 0.92). Cronbach’s alpha exceeded
0.80 in the three studies for the Satisfaction domain (Cronbach’s
alpha: 0.82, 0.85, 0.84) and the Psychological Reward domain
(0.84, 0.82, 0.83) but was less than 0.60 for the Aversion domain
(0.50, 0.55, and 0.56). CONCLUSION: The validity of the pos-
tulated multidimensional framework of the SEI is conﬁrmed and
supported by the data. Although reliability (internal consistency)
of the Aversion domain was not high, excellent reliability was
